Updated Meta-analysis on HER2 Polymorphisms and Risk of Breast Cancer: Evidence from 32 Studies

Background: Several studies have been performed to investigate the association of the HER2 Ile655Valpolymorphism and breast cancer risk. However, the results were inconsistent. To understand the preciserelationship, a meta-analysis was here conducted. Materials and
Methods: A search of PubMed conducted toinvestigate links between the HER2 Ile655Val polymorphism and breast cancer, identified a total of 32 studies, ofwhich 29, including 14,926 cases and 15,768 controls, with odds ratios (ORs) with 95% confidence intervals wereused to assess any association.
Results: In the overall analysis, the HER2 Ile655Val polymorphism was associatedwith breast cancer in an additive genetic model (OR=1.136, 95% CI 1.043-1.239, p=0.004) and in a dominantgenetic (OR=1.118, 95% CI 1.020-1.227, p=0.018), while no association was found in a recessive genetic model.On subgroup analysis, an association with breast cancer was noted in the additive genetic model (OR=1.111,95% CI: 1.004-1.230, p=0.042) for the Caucasian subgroup. No significant associations were observed in Asiansand Africans in any of the genetic models.
Conclusions: In summary, our meta-analysis findings suggest thatthe HER2 Ile655Val polymorphism is marginally associated with breast cancer susceptibility in worldwidepopulations with additive and dominant models, but not a recessive model.